Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 580 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bite Clear all
Completed Phase 3 Interventional

Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia

NCT00000170
View directory record Official record
Conditions
Amblyopia
Interventions
Atropine, Eye Patch
Drug · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
Up to 6 Years
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Oct 21, 2026, 9:04 AM EDT
Completed No phase listed Observational

Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion

NCT02026466
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
11
States / cities
Mesa, Arizona • Phoenix, Arizona • Torrance, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 21, 2026, 9:04 AM EDT
Recruiting Not applicable Interventional

Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion

NCT06348394
View directory record Official record
Conditions
Left Atrial Appendage Closure
Interventions
Intracardiac Echocardiography, Traditional transesophageal echocardiography
Device
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 90 Years
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 21, 2026, 9:04 AM EDT
Completed Phase 3 Interventional

Peripheral Facilitated Antegrade Steering Technique in Chronic Total Occlusions

NCT01246505
View directory record Official record
Conditions
Chronic Total Occlusion
Interventions
CTO Crossing and Percutaneous transluminal angioplasty
Device
Lead sponsor
BridgePoint Medical
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Oct 21, 2026, 9:04 AM EDT
Completed Phase 3 Interventional Results available

Full-Time Occlusion Therapy for Intermittent Exotropia in Children

NCT05462821
View directory record Official record
Conditions
Intermittent Exotropia
Interventions
Eye Patch
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
3 Years to 8 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
25
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Berkeley, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 21, 2026, 9:04 AM EDT
Completed Phase 2 Interventional

A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central Retinal Artery Occlusion (CRAO)

NCT06178055
View directory record Official record
Conditions
Central Retinal Artery Occlusion
Interventions
KUS121 high dose, KUS121 low dose, Sham procedure
Drug
Lead sponsor
Kyoto Drug Discovery and Development Co., Ltd.
Industry
Eligibility
20 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
11
States / cities
Encino, California • Huntington Beach, California • Oakland, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 21, 2026, 9:04 AM EDT
Terminated Phase 4 Interventional Results available

Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis

NCT00924950
View directory record Official record
Conditions
Plaque Psoriasis, Psoriasis Vulgaris
Interventions
Taclonex Ointment and Hydrogel Patch, Taclonex Ointment
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 21, 2026, 9:04 AM EDT
Completed Phase 4 Interventional Results available

Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO

NCT02503540
View directory record Official record
Conditions
Retinal Vein Occlusion, Diabetic Macular Edema, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion
Interventions
Aflibercept
Drug
Lead sponsor
Justis Ehlers
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 21, 2026, 9:04 AM EDT
Active, not recruiting Phase 1 Interventional

Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

NCT03319940
View directory record Official record
Conditions
Small Cell Lung Carcinoma
Interventions
Tarlatamab, Pembrolizumab, CRS Mitigation Strategies
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
15
States / cities
Duarte, California • New Haven, Connecticut • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 21, 2026, 9:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Treatment of Central Retinal Vein Occlusion Using Stem Cells Study

NCT03981549
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
Autologous Bone Marrow CD34+ Stem Cells, Sham Therapy
Biological
Lead sponsor
The Emmes Company, LLC
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Oct 21, 2026, 9:04 AM EDT
Completed Phase 1 Interventional

Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders

NCT00071227
View directory record Official record
Conditions
Macular Degeneration, Retinal Vein Occlusion
Interventions
Triamcinolone Acetonide (TAC-PF)
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 9:04 AM EDT
Completed Not applicable Interventional Results available

QL vs PENG for Analgesia After Hip Arthroplasty

NCT05710107
View directory record Official record
Conditions
Block, Hip Replacement, Postoperative Pain
Interventions
PENG + LFC Block, QL Block
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 21, 2026, 9:04 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Single Site, Masked, Randomized, Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion

NCT01085734
View directory record Official record
Conditions
Retinal Vein Occlusions
Interventions
Avastin, Osurdex
Drug
Lead sponsor
Maturi, Raj K., M.D., P.C.
Individual
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 21, 2026, 9:04 AM EDT
Terminated Phase 4 Interventional Results available

Low Dose IV Dexamethasone in Prolonging Caudal Anesthesia in Children Undergoing Genitourinary Surgery

NCT02436265
View directory record Official record
Conditions
Surgery
Interventions
Dexamethasone, Ropivacaine
Drug
Lead sponsor
Indiana University
Other
Eligibility
2 Years to 10 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 21, 2026, 9:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease

NCT02719665
View directory record Official record
Conditions
Peripheral Arterial Disease, Claudication, Claudication, Intermittent, Vascular Occlusion, Vascular Calcification, Vascular Diseases, Osteoarthritis
Interventions
SPM Emulsion, Dose-modality, SPM Softgel, Dose-Modality, Placebo Softgel
Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 21, 2026, 9:04 AM EDT
Completed Phase 3 Interventional Results available

GORE Embolic Protection With Reverse Flow

NCT00594100
View directory record Official record
Conditions
Carotid Artery Stenosis
Interventions
GORE Flow Reversal System (GFRS)
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Buffalo, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 27, 2013 · Synced Oct 21, 2026, 9:04 AM EDT
Recruiting Not applicable Interventional

tDCS and Urge in BFRBs

NCT07019571
View directory record Official record
Conditions
Repetitive Compulsive Behavior
Interventions
Wireless Multichannel Transcranial Current Stimulator (tDCS), Cue exposure, Boredom induction
Device · Behavioral
Lead sponsor
Gopalkumar Rakesh
Other
Eligibility
18 Years to 60 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 21, 2026, 9:04 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

REduction of Contrast Via DyeVert Used in CTO Procedures

NCT03118544
View directory record Official record
Conditions
Chronic Total Occlusion of Coronary Artery
Interventions
DyeVert System
Device
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 21, 2026, 9:04 AM EDT
Active, not recruiting Not applicable Interventional

Amplatzer Amulet LAAO vs. NOAC

NCT04226547
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Bleeding
Interventions
Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder), Non-Vitamin K Oral Antagonists
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
79
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 21, 2026, 9:04 AM EDT
Not listed Phase 1 Interventional

Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

NCT04120311
View directory record Official record
Conditions
Macular Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis
Interventions
Episcleral Dexamethasone
Drug
Lead sponsor
Targeted Therapy Technologies, LLC
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 21, 2026, 9:04 AM EDT
Completed Phase 2 Interventional

A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery

NCT01245634
View directory record Official record
Conditions
Coronary Heart Disease, Graft Occlusion, Vascular
Interventions
Placebo, RO4905417
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 85 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
27
States / cities
Huntsville, Alabama • Tucson, Arizona • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 21, 2026, 9:04 AM EDT
Completed Phase 4 Interventional Results available

Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion

NCT01710839
View directory record Official record
Conditions
Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions
Interventions
0.5mg Ranibizumab, Targeted Pan Retinal Photocoagulation
Drug · Procedure
Lead sponsor
Charles C Wykoff, PhD, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Houston, Texas • Katy, Texas • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2017 · Synced Oct 21, 2026, 9:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tick-borne Illness and Clothing Study

NCT01454414
View directory record Official record
Conditions
Tick Bites, Tick-borne Illness
Interventions
Permethrin Impregnated Uniforms
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 21, 2026, 9:04 AM EDT
Enrolling by invitation Phase 4 Interventional

Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections

NCT07456826
View directory record Official record
Conditions
Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion, Diabetic Retinopathy (DR)
Interventions
Chloroprocaine Ophthalmic Gel 3% (IHEEZO), Sham Subconjunctival Injection, Proparacaine Hydrochloride Ophthalmic Solution 0.5%, Lidocaine Hydrochloride Injection 2%
Drug · Procedure
Lead sponsor
Harrow Inc
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 21, 2026, 9:04 AM EDT